Masters Pharmaceuticals Ltd

Albion Ventures LLP invest £2.65m in Masters Pharmaceuticals Ltd

Albion Ventures has invested £2.65m in Masters Pharmaceuticals Ltd ("Masters") as sole investor. Masters is a specialist international supplier and distributor of pharmaceutical products and the investment will be used for continued expansion in its core markets of Latin America, the Middle East and the Caribbean. Masters is also seeking to open new markets in Asia.

Peter Counsell of Meta Corporate Finance advised the existing Shareholders, including the founder Zulf Masters, on the investment from Albion Ventures.

Masters was founded in 1984 and operates primarily in the international supply of licensed drugs into unlicensed territories providing access for international markets to drugs that are commonly available in the US and Europe but hard to access from outside those markets. Other activities are centred on specialist wholesale distribution of generic and branded pharmaceuticals.

Masters has appointed Bill Burns as non-executive chairman of its Board. Bill is a high profile figure in the pharmaceutical industry with over 40 years experience in the sector most recently as CEO of Roche Pharmaceuticals and will build on Masters’ current strong organic growth through targeted acquisition and partnering opportunities.

Andrew Elder, Partner, Albion Ventures said: “Masters is an attractive investment for us because it operates within a global market that is experiencing a huge increase in demand for leading US and European drugs and treatments. There is real potential for it to become the market leader in this space and the appointment of Bill Burns adds real depth to an already talented and experienced management team.”

Back to Transactions